GLP-1 Compounding: Lilly Takes Advertising Complaints To NAD

 
• By Sue Sutter

Lilly’s complaint to the National Advertising Division, a self-regulatory forum for industry, about an Oregon clinic’s claims expands the battlefront against widespread compounding of GLP-1 products for weight loss and diabetes treatment.

Woman on scale
Lilly is battling companies marketing compounded GLP-1 products for weight loss. (Shutterstock)

More from Marketing & Advertising

More from Compliance